Navigation Links
Regional Biotech Association Warns Vermont Legislation Could Have Profound Negative Impact
Date:3/27/2009

- Shumlin Promoting Senate Bill S. 48 Today; Will Thwart Burgeoning Biotechnology Industry, Costing Jobs and Research Funds in Vermont -

MONTPELIER, Vt., March 27 /PRNewswire/ -- The region's largest biotechnology association today warned that a bill under consideration by the Vermont Legislature will create the most restrictive and onerous regulatory environments for biotechnology growth and development not only in New England, but in the entire nation. Senate Bill 48, an Act Relating to the Marketing of Prescribed Products, is the focus of a presentation today at the State House by Senate President Peter Shumlin.

"The Legislation's radical expansion of Vermont's existing and strict biopharmaceutical marketing laws promises to hinder significantly the development of the biotechnology industry in this state," said Paula Newton, Chair of the New England Biotech Association (NEBA).

NEBA serves as the regional policy and public affairs voice for the biotechnology and biopharmaceutical community, representing state biotech associations, companies, academic institutions, and other organizations consisting of more than 800 entities.

Vermont law already heavily regulates biopharmaceutical marketing activities by requiring the disclosure of the value, nature and purpose of certain marketing related expenses by pharmaceutical manufacturers of just $25 or more in value, among other things. The bill would expand existing regulation by limiting compensation and other payments between biopharmaceutical manufacturers and physicians -- including educational materials. And it would broadly expand already onerous disclosure requirements to include competitively sensitive information concerning clinical trials. Furthermore, IMS Health this month reported that annual U.S. prescription sales growth was just 1.3 percent in 2008, the lowest rate since 1963, according to data maintained by CMS -- making the stated purpose of the Legislation, controlling drug costs, moot.

"With the enactment of these over-the-top restrictions, Vermont's pharmaceutical marketing law will be far more severe than those of any other New England state. Such a uniquely sweeping expansion of the regulatory climate in Vermont will have a chilling effect on the growth of the industry in this state," said Newton. "These requirements would certainly discourage biotechnology manufacturers from participating in clinical trials and academic research in Vermont, since reported information would include competitively sensitive and proprietary information, making it more prudent to conduct research in one of the 49 other states," she continued. "We urge reasonable elected officials who care about future jobs and the health care system in Vermont to reject this legislation."

Two other states, Colorado and New Mexico, have recently rejected marketing restriction legislation far less extreme than the Vermont bill as bad policy with unintended negative consequences for the life sciences industry and the jobs it produces

NEBA is a non-profit, member-driven organization comprised of state biotech associations, companies, academic institutions, and other organizations with a collective mission to support and grow the biotechnology industry in New England. NEBA serves as the regional policy and public affairs voice for the biotechnology and biopharmaceutical industry, and is committed to ensuring that New England remains a global leader in biotechnology and the life sciences.

NEBA members include the largest biotech associations in those states, including the Biotech Association of Maine, Connecticut United for Research Excellence (CURE), New Hampshire Bio/Medical Council, Rhode Island BioGroup, Massachusetts Biotechnology Council, Massachusetts High Technology Council, and the Biotech Association of Vermont (in formation).

To find out more about NEBA, visit www.newenglandbiotech.org


'/>"/>
SOURCE New England Biotech Association
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Shasta Regional Medical Center Awarded Full Accreditation from the Joint Commission
2. New Regional Biotech Association Formed
3. China Biopharma Reaches Agreement with a Regional Pharma to Launch New Pharmaceutical Products
4. Hcareers.com Strengthens Local Market Candidate Reach Through RegionalHelpWanted.com Acquisition
5. BioSpace.com Strengthens Local Market Candidate Reach Through RegionalHelpWanted.com Acquisition
6. JobLoft.com Strengthens Local Market Candidate Reach Through RegionalHelpWanted.com Acquisition
7. onTargetjobs Announces Acquisition of RegionalHelpWanted.com
8. A Magnetic Gift: Sumter Regional Hospital Receives New MRI as Charitable Donation From Siemens
9. Center for Molecular Medicine Only Regional Provider of Test Suggested in FDA Alert on Prescribing Codeine to Nursing Mothers
10. Biotechnology Value Fund, L.P. Announces Overwhelming Support to Remove the Board of Directors of Avigen, Inc. at Special Meeting of Stockholders
11. Rigel to Present at Citis Biotech Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... -- Infectex Ltd., a Russian portfolio company of Maxwell Biotech Venture Fund ... to the standard drug therapy regimen in patients with multidrug-resistant pulmonary tuberculosis (MDR-TB). SQ109 ... USA ) and the US National Institutes of Health. ... ... ...
(Date:3/27/2017)... , March 27, 2017 The new ... a comprehensive library of reports on Valero Energy , ... fuels and petrochemical industries. ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO) ... production to go green. Ethanol today, even though touted as ...
(Date:3/27/2017)... DIEGO , March 27, 2017  Trovagene, Inc. ... that its Chief Executive Officer, Bill Welch , ... April 4, 2017 at 9:00 AM EDT at the ... .  Bill Welch, and Chief Scientific Officer, Mark ... with investors during the conference.   The presentation ...
(Date:3/24/2017)... MARIETTA, Ga. , March 24, 2017 ... and biopharmaceutical company utilizing human placental tissue allografts and ... therapies for multiple sectors of healthcare, announced today  that ... New York , NY.  Parker H. ... , Chief Financial Officer, Christopher M. Cashman , ...
Breaking Biology Technology:
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access System ... over the next decade to reach approximately $1,580 million by 2025. ... forecasts for all the given segments on global as well as ...
(Date:3/23/2017)... , Mar. 23, 2017 Research and Markets ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 8.8% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
(Date:3/22/2017)... 2017 Optimove , provider of ... such as 1-800-Flowers and AdoreMe, today announced two ... Replenishment. Using Optimove,s machine learning algorithms, these features ... replenishment recommendations to their customers based not just ... customer intent drawn from a complex web of ...
Breaking Biology News(10 mins):